Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories have?
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories has 84 citations in the OpenAlex counts ScholarIQ stores.
When was Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories published?
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories has 2020 year in the ScholarIQ index.
What is the open-access status of Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories?
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories has bronze oa status in the ScholarIQ index.
What is the DOI of Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories?
The DOI for Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories is on the source record.
What is the PMID of Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories?
The PMID for Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories is on the source record.
What is the OpenAlex record for Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories?
The OpenAlex for Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories is on the source record.